Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-ALL2018 Blinatumomab Supplementary Study in Pediatric Precursor B-cell ALL
ChiCTR2200062866Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jun 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of blinatumomab in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Beijing Children's Hospital. Primary endpoints: minimal residual disease (MRD), remission state of bone marrow and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2200062866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062866.